FDA Shares New Findings in Valsartan Investigation

Drug Industry Daily
A A
The FDA announced on Friday that the impurities found in valsartan-containing blood pressure drugs may have been caused by specific chemicals and reaction conditions in the manufacturing process of the drug’s API.

To View This Article:

Login

Subscribe To Drug Industry Daily